LV10199A - Neglikozileta proteina farmaceitiskais preparats un ta iegusanas panemiens - Google Patents

Neglikozileta proteina farmaceitiskais preparats un ta iegusanas panemiens

Info

Publication number
LV10199A
LV10199A LV930463A LV930463A LV10199A LV 10199 A LV10199 A LV 10199A LV 930463 A LV930463 A LV 930463A LV 930463 A LV930463 A LV 930463A LV 10199 A LV10199 A LV 10199A
Authority
LV
Latvia
Prior art keywords
suppression
pharmaceutical preparation
glycosylate
protein
glycosylate protein
Prior art date
Application number
LV930463A
Other languages
English (en)
Other versions
LV10199B (en
Inventor
Ulrich Kohnert
Rainer Rudolph
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of LV10199A publication Critical patent/LV10199A/lv
Publication of LV10199B publication Critical patent/LV10199B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LVP-93-463A 1989-12-20 1993-06-02 Pharmaceutical preparation of unglycosylated protein and method of preparation thereof LV10199B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3942143A DE3942143A1 (de) 1989-12-20 1989-12-20 T-pa pro stabilisierung
PCT/EP1990/002251 WO1991008766A1 (de) 1989-12-20 1990-12-19 t-PA pro STABILISIERUNG

Publications (2)

Publication Number Publication Date
LV10199A true LV10199A (lv) 1994-10-20
LV10199B LV10199B (en) 1995-04-20

Family

ID=6395926

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-463A LV10199B (en) 1989-12-20 1993-06-02 Pharmaceutical preparation of unglycosylated protein and method of preparation thereof

Country Status (13)

Country Link
US (1) US5352453A (lv)
EP (1) EP0458939B1 (lv)
JP (1) JPH0657661B2 (lv)
KR (1) KR920700684A (lv)
AT (1) ATE103178T1 (lv)
AU (1) AU633684B2 (lv)
CA (1) CA2046929C (lv)
DE (2) DE3942143A1 (lv)
FI (1) FI96000C (lv)
HU (2) HUT59610A (lv)
LV (1) LV10199B (lv)
NO (1) NO305583B1 (lv)
WO (1) WO1991008766A1 (lv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
WO1992018157A1 (de) * 1991-04-16 1992-10-29 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
ATE173739T1 (de) * 1992-04-30 1998-12-15 Cor Therapeutics Inc Stabile zusammensetzung von polypeptiden
US6001480A (en) * 1993-06-11 1999-12-14 Zexel Corporation Amorphous hard carbon film and mechanical parts coated therewith
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
EP0218112B1 (en) * 1985-09-10 1992-12-09 Eisai Co., Ltd. Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
JPH0678241B2 (ja) * 1986-04-02 1994-10-05 エーザイ株式会社 ｔＰＡ医薬組成物
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
AU4187389A (en) * 1988-08-02 1990-03-05 Invitron Corporation Method for preparing tpa compositions
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
JPH0813750B2 (ja) * 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤

Also Published As

Publication number Publication date
AU633684B2 (en) 1993-02-04
CA2046929A1 (en) 1991-06-21
JPH0657661B2 (ja) 1994-08-03
HU208637B (en) 1993-12-28
NO913118D0 (no) 1991-08-09
ATE103178T1 (de) 1994-04-15
WO1991008766A1 (de) 1991-06-27
FI96000B (fi) 1996-01-15
NO305583B1 (no) 1999-06-28
FI96000C (fi) 1996-04-25
FI913909A0 (fi) 1991-08-19
AU7037591A (en) 1991-07-18
EP0458939B1 (de) 1994-03-23
DE59005128D1 (de) 1994-04-28
HUT59610A (en) 1992-06-29
DE3942143A1 (de) 1991-06-27
NO913118L (no) 1991-08-09
LV10199B (en) 1995-04-20
JPH03505465A (ja) 1991-11-28
US5352453A (en) 1994-10-04
EP0458939A1 (de) 1991-12-04
HU912742D0 (en) 1992-01-28
CA2046929C (en) 1997-01-14
KR920700684A (ko) 1992-08-10

Similar Documents

Publication Publication Date Title
TR199902529T2 (xx) Etkinle�tirilmi� protein C form�lasyonlar�.
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
CS653586A3 (en) Pharmaceutical containing 7-isopropoxyisoflavone
AU3183389A (en) Human relaxin formulation
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
EP0151989A3 (en) Means for the treatment of cardiac diseases
DE69331739D1 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
DK0460062T3 (da) Huperzin A-analoger
HU912738D0 (en) K2p pro-stabilization
LV10199A (lv) Neglikozileta proteina farmaceitiskais preparats un ta iegusanas panemiens
PL324690A1 (en) Improved therapeutic agents
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
FR2658190B1 (fr) Esters d'aminoacides de l'hydroquinone, leur procede de preparation et compositions pharmaceutiques ou cosmetiques les contenant.
IT8322486A0 (it) N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8420355A0 (it) Derivato del p-aminofenolo conattivita'mucosecretolitica-fluidificante e antipiretica, procedimento per lasua preparazione e sue composizioni farmaceutiche.
IT8422258A0 (it) Derivato del(-)-6,6,-dimetilbiciclo[3.3.1] ept-2-ene-2-metanolo ad attivita'mucosecretolitica, procedimento per la sua preparazione e sue composizioni farmaceutiche
IT8422259A0 (it) Derivato del (-)-6,6-dimetilbiciclo [3.1.1] ept-2-ene-2-etanolo, ad attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
MX9705119A (es) Interferona modificada quimicamente.
IE45326L (en) Gold-containing pharmaceutical composition
IT8522989A0 (it) Frazione ottenuta da listeria monocytogenes avente attivita'terapeutica, procedimento per lasua preparazione e composioni farmaceutiche che la contengono.
ITMI921438A1 (it) Composto dotato di attivita' mitostatica ed antiradicalica per il trattamento della psoriasi